Steward Partners Investment Advisory’s Axsome Therapeutics AXSM Stock Holding History

Steward Partners Investment Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35	Closed	-$5.92K	–	4672
2026 Q1	$5.92K	Hold	35	–	–	﹤0.01%	3743
2025 Q4	$6.39K	Buy	35 +25	+250%	+$3.49K	﹤0.01%	3613
2025 Q3	$1.22K	Hold	10	–	–	﹤0.01%	4023
2025 Q2	$1.04K	Buy	10 +6	+150%	+$635	﹤0.01%	3850
2025 Q1	$467	Hold	4	–	–	﹤0.01%	3866
2024 Q4	$338	Buy	+4	New	+$368	﹤0.01%	3878
2022 Q4	–	Sell	-214	Closed	-$10K	–	3365
2022 Q3	$10K	Sell	214 -4,286	-95%	-$214K	﹤0.01%	2518
2022 Q2	$172K	Hold	4,500	–	–	﹤0.01%	1268
2022 Q1	$186K	Hold	4,500	–	–	﹤0.01%	1328
2021 Q4	$170K	Buy	4,500 +700	+18%	+$25.8K	﹤0.01%	1379
2021 Q3	$125K	Buy	3,800 +3,700	+3,700%	+$144K	﹤0.01%	1458
2021 Q2	$7K	Sell	100 -400	-80%	-$24K	﹤0.01%	6359
2021 Q1	$28.3K	Buy	+500	New	+$35.2K	﹤0.01%	2295

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steward Partners Investment Advisory's AXSM Position: Q2 2026 in Review

Steward Partners Investment Advisory sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 35 shares — an estimated $5.92K sold.

Steward Partners Investment Advisory first reported a position in AXSM in Q1 2021 and held it in 13 quarters. The position peaked at $186K in Q1 2022. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Steward Partners Investment Advisory reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Steward Partners Investment Advisory sold 35 Axsome Therapeutics shares in Q2 2026, an estimated $5.92K.
Steward Partners Investment Advisory first reported a position in Axsome Therapeutics in Q1 2021 and held it in 13 quarters.
Steward Partners Investment Advisory's Axsome Therapeutics position peaked at $186K in Q1 2022.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.